Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000113849 | SCV000244477 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2015-08-10 | reviewed by expert panel | curation | IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 5 based on posterior probability = 0.997 |
Color Diagnostics, |
RCV000583576 | SCV000689086 | pathogenic | Hereditary cancer-predisposing syndrome | 2020-10-12 | criteria provided, single submitter | clinical testing | This missense variant replaces arginine with threonine at codon 2659 of the BRCA2 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). Functional RNA studies have shown that this variant causes skpping of exon 17 and reduced DNA repair activity (PMID: 18451181). This variant has been reported in individuals affected with breast/ovarian cancer in the literature (PMID: 16489001, 25447315). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. |
Breast Cancer Information Core |
RCV000113849 | SCV000147236 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 2 | 2003-12-23 | no assertion criteria provided | clinical testing |